Amphotericin B potentiates the antifungal effects of 5-fluorocytosine and rifampicin, probably by increasing the penetration of these agents through the fungal cytoplasmic membrane.
The range of inhibitors active against many cells and infective agents is often limited by cell permeability. Both the study of cell physiology and the potential clinical use of drugs could be advanced if the permeability barrier of the cytoplasmic membrane could be circumvented or controlled without irreparable damage to cells. This is partially accomplished in bacteria by use of ethylenediaminetetraacetate (EDTA) (1). Here we report preliminary results with another technique that may be of general use with eukaryotic cells.
The present work used yeast in an experimental system in which low concentrations of amphotericin B potentiated the effects of antibiotics. Amphotericin B is a polyene that binds to sterols and makes "holes" in cell membranes of eukaryotic cells (2) and mycoplasma (3) . It seemed possible that low concentrations of amphotericin B, insufficient to kill when used alone, might cause transient membrane lesions that enhance the uptake of other molecules.
In a previous report, some of us showed that an antifungal agent, 5-fluorocytosine (5-FCyt), could be effective in synergistic combinations with low levels of amphotericin B against fungi that are relatively resistant to each agent when used alone (4 (6) : a decrease of 100-fold or more in colony count caused by the drugs in combination, as compared with the count when the drugs are used singly. In every case, the drugs in combination were used at concentrations well below their respective MIC. In each synergy study, a standard inoculum of 1 X 105 cells was incubated for 7 days at 24-26 C. Suspensions of cells were inoculated into tubes containing amphotericin B and rifampicin in the amounts noted and viability studies were performed on subcultures at 0 time and 7 days. All cultures were incubated at 25°C, and in the dark, because of the sensitivity of the drugs to light. Rifampicin alone, at concentrations up to 100 ,ug/ml, had no lethal effect on the wild-type yeasts; and amphotericin B, at the concentrations used, only slowed growth slightly. The combined use of the drugs was synergistic at several different concentrations. These data are shown in Table 1 and Fig. 2 . In every case the concentrations of drugs used in the combination were well below the MIC. The MIC for the Hoffmann-LaRoche S. cerevisiae wi d type is much higher than that for the aboratory strain A364a, but in both cases synergy was demonstrated in the appropriate ranges of concentrations. Fig. 3 shows the dose-response curves for amphotericin B alone and in combination with rifampicin, based on incorporation of ['Hluracil into acid-insoluble material of S. cerevisiae A364a. Rifampicin alone had little or no effect on ['H ]uracil incorporation. Amphotericin B alone showed a 20% inhibition at a concentration of 0.1 ,ug/ml; the combination of the two antibiotics inhibited yeast growth up to a maximum of 60%. These findings support those about the synergy demonstrated by colony counts.
As has already been reported (2), the effects of amphotericin B alone were partially dependent on the ratio of antibiotic to cell density, rather than to the absolute concentration of the drug. Similar effects were noted with rifampicin; for example, high concentrations of rifampicin alone (100 ,g/ml) inhibited RNA synthesis over a 3-hr period by 46, 18 , and 7% at densities of 0.4 X 106, 0.6 X 106, and 1.3 X 106 cells/ml, respectively. Nevertheless, at every cell density tested, significant potentiation of rifampicin action by amphotericin B could be demonstrated over a wide range of concentrations (as in Fig. 3 ).
Rifampicin also inhibited the growth of a fragile mutant of S. cerevisiae, H-15. As in the case of wild-type cells treated with amphotericin B, the inhibition of RNA synthesis was not complete even in the presence of high levels of rifampicin. This suggested that synthesis of particular species of RNA was selectively inhibited. Fragility of the strain facilitated analysis of the RNA. The acrylamide gel analysis in Fig. 4 indicates that a specific reduction of incorporation occurred in the characteristic RNA peaks at 35 S, 25 S, and 18 S; heterogeneous RNA continued to be formed. Other experiments have shown that the RNA formed in the presence of rifampicin is unmethylated and unstable, and that in cell lysates much of it is found in polyribosomes, rather than in ribosomal precursors. These findings thus suggest that the RNA whose synthesis is inhibited by rifampicin is ribosomal.
DISCUSSION
The antifungal synergism of amphotericin B with rifampicin or 5-FCyt is probably due to an alteration in the permeability barrier of the surface membrane, resulting in increased pene- (11) .
In the case of 5-FCyt, analogous to the effects of 5-fluorouracil, it is likely that the drug leads to the production of faulty messenger RNA (12) , and possibly of defective RNA as well (13) . Thus, the effectiveness of the drug is likely to be dependent on the concentrations introduced into the cell. In this study, synergy has been defined in terms of cell viability The biochemical results also show a consistent effect with the drug combinations that is greater than the effect of the two drugs used separately. The effects of the drugs on shortterm growth or RNA synthesis are much less marked than the reduction in colony counts at 7 days, but they are consistent with a cumulative inhibition that finally kills the cells.
These studies have obvious clinical implications. At present, most systemic fungal infections must be treated exclusively with amphotericin B or other polyenes (14) . Unfortunately, these are toxic drugs, with a high incidence of treatment failures (15) . Antifungal synergism may provide opportunities for more effective therapy by permitting the use of lower doses of these agents. On the other hand, the increased potency of the combinations may be counterbalanced by increased toxicity to host cells that would obviate their clinical usefulness.
